反応式
[CH3:1][N:2]([CH3:35])[CH2:3][CH2:4][N:5]1[CH2:10][CH2:9][N:8]([C:11]2[N:12]=[CH:13][C:14]3[CH:20]=[C:19]([C:21]4[CH:26]=[CH:25][CH:24]=[CH:23][CH:22]=4)[C:18]([C:27]4[CH:34]=[CH:33][C:30]([CH:31]=O)=[CH:29][CH:28]=4)=[N:17][C:15]=3[N:16]=2)[CH2:7][CH2:6]1.FC(F)(F)C(O)=O.[NH:43]1[CH2:48][CH2:47][CH:46]([C:49]2[NH:50][C:51]([C:54]3[CH:59]=[CH:58][N+:57]([O-:60])=[CH:56][CH:55]=3)=[N:52][N:53]=2)[CH2:45][CH2:44]1.CCN(CC)CC.CC(O)=O.C(O[BH-](OC(=O)C)OC(=O)C)(=O)C.[Na+]>CN(C=O)C.CCOC(C)=O>[CH3:1][N:2]([CH3:35])[CH2:3][CH2:4][N:5]1[CH2:10][CH2:9][N:8]([C:11]2[N:12]=[CH:13][C:14]3[CH:20]=[C:19]([C:21]4[CH:26]=[CH:25][CH:24]=[CH:23][CH:22]=4)[C:18]([C:27]4[CH:34]=[CH:33][C:30]([CH2:31][N:43]5[CH2:48][CH2:47][CH:46]([C:49]6[NH:50][C:51]([C:54]7[CH:59]=[CH:58][N+:57]([O-:60])=[CH:56][CH:55]=7)=[N:52][N:53]=6)[CH2:45][CH2:44]5)=[CH:29][CH:28]=4)=[N:17][C:15]=3[N:16]=2)[CH2:7][CH2:6]1参加物
8
反応物 5
生成物 1
試薬・触媒・溶媒 2
実験手順
To a solution of 4-(2-{{4-[2-dimethylamino)ethyl]piperazine-1-yl}-6-phenylpyrido[2,3-d]pyrimidin-7-yl)benzaldehyde (6-5) (100 mg, 0.214 mmol) in DMF (5 mL) was added 4-(5-piperidin-4-yl-4H-1,2,4-triazol-3-yl)pyridine 1-oxide trifluoroacetate (B) (92 mg, 0.257 mmol) followed by Et3N (80 μL, 0.51 mmol), AcOH (91 μL, 1.5 mmol) and sodium triacetoxyborohydride (59 mg, 0.28 mmol). The reaction mixture was allowed to stir for 12 hr then diluted with EtOAc and washed with NaHCO3 (sat.), dried with MgSO4, filtered, and concentrated under reduced pressure. The oily residue was purified by reverse phase HPLC (20% MeCN/80% H2O to 47% MeCN/53% H2O) to afford the title compound. LRMS m/z (M+H) Calcd.: 696.9, found 696.1.
後処理
- washwashed with NaHCO3 (sat.)
- dry with materialdried with MgSO4
- filtrationfiltered
- concentrationconcentrated under reduced pressure
- customThe oily residue was purified by reverse phase HPLC (20% MeCN/80% H2O to 47% MeCN/53% H2O)
出典と根拠
- ORDレコード
- ord-23c92cc9c8b247d7b5f3fe935a7026c8
- 出典データセット
- uspto-grants-2009_06
- 特許番号
- US07544677B2
関連ノート
読み込み中…